Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Simmons

Showing results (701-710 of 707) with videos related to

Pageof 71
Sort By:
You have reached the last page of results.This site can display upto 707 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 2, 2021
Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 StudyAndrea Loehr, Akash Patnaik, David Campbell, et al.
Gynecologic Oncology|March 23, 2021
Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2Gottfried E Konecny, Amit M Oza, Anna V Tinker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 23, 2020
Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 StudyWassim Abida, David Campbell, Akash Patnaik, et al.
Cancer Discovery|September 26, 2013
Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLCAnnette O Walter, Robert Tjin Tham Sjin, Henry J Haringsma, et al.
European Urology|June 5, 2023
Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 StudyWassim Abida, David Campbell, Akash Patnaik, et al.
Nature Genetics|November 7, 2017
Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancersCollin M Blakely, Thomas B K Watkins, Wei Wu, et al.
Cancer Discovery|June 8, 2017
Secondary Somatic Mutations Restoring <i>RAD51C</i> and <i>RAD51D</i> Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian CarcinomaOlga Kondrashova, Minh Nguyen, Kristy Shield-Artin, et al.
Pageof 71

Showing results (701-710 of 707) with videos related to

Sort By:
Pageof 71
You have reached the last page of results.This site can display upto 707 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 2, 2021
Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 StudyAndrea Loehr, Akash Patnaik, David Campbell, et al.
Gynecologic Oncology|March 23, 2021
Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2Gottfried E Konecny, Amit M Oza, Anna V Tinker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 23, 2020
Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 StudyWassim Abida, David Campbell, Akash Patnaik, et al.
Cancer Discovery|September 26, 2013
Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLCAnnette O Walter, Robert Tjin Tham Sjin, Henry J Haringsma, et al.
European Urology|June 5, 2023
Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 StudyWassim Abida, David Campbell, Akash Patnaik, et al.
Nature Genetics|November 7, 2017
Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancersCollin M Blakely, Thomas B K Watkins, Wei Wu, et al.
Cancer Discovery|June 8, 2017
Secondary Somatic Mutations Restoring <i>RAD51C</i> and <i>RAD51D</i> Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian CarcinomaOlga Kondrashova, Minh Nguyen, Kristy Shield-Artin, et al.
Pageof 71